Slide 1: CSL Australia Investor Site Tour Presentations
For immediate release 11 April 2024 CSL Australia Investor Site Tour Presentations For personal use only The presentation materials to be used for an Investor Site Tour being conducted by CSL (ASX:CSL; USOTC:CSLLY) in Melbourne today are attached for the information of investors. Authorised By Fiona
Slide 2: Investor Tour CSL Behring & CSL Seqirus
For personal use only Investor Tour CSL Behring & CSL Seqirus April 2024 1
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and For personal use only CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 4: Acknowledgement of Country
Acknowledgement of Country For personal use only CSL acknowledges Traditional Owners of Country throughout Australia and recognises their continuing connection to lands, waters and communities. We pay our respects to all Aboriginal and Torres Strait Islander cultures; and to Elders past and present.
Slide 5: CSL Behring Broadmeadows Investor Tour
For personal use only CSL Behring Broadmeadows Investor Tour Mike Deem Andrew Hodder Head Of Operations Manufacturing & Site Head April 2024 CSL Behring CSL Behring Australia
Slide 6: Visitor Safety Procedures
Visitor Safety Procedures For personal use only While you are in the facility you will be escorted by CSL Behring personnel In the event of an emergency follow the instructions provided by your guide Alert Tone – “BEEP-BEEP-BEEP” • Standby and await instructions of wardens Evacuate Tone – “WHOOP-WHO
Slide 7: Site Safety Rules
For personal use only Site Safety Rules
Slide 8: Who we are
Who we are For personal use only CSL is a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives. Cheryl Blackwell Johnson Living with HAE 7
Slide 9: Leading global biotech company
Leading global biotech company We are a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives For personal use only 40 around the world + Countries of operations US
Slide 10: CSL group operating structure
CSL group operating structure For personal use only Global Biotherapeutics Leader Global Influenza Vaccines Leader Global Specialty Pharma Leader • One of the world’s largest collectors • One of the largest influenza vaccine • Global specialty pharmaceuticals of plasma and providers of plasma compan
Slide 11: CSL Behring: Driving sustainable, profitable growth
CSL Behring: Driving sustainable, profitable growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION 1 2 3 Deploy Rika, Deliver Horizon 1 yield Outpace market Nomogram A/I, improvements; advance growth in Ig, digital transformation Horizo
Slide 12: CSL Behring – Global manufacturing presence
CSL Behring – Global manufacturing presence For personal use only Bern, Broadmeadows, Marburg, Kankakee, Wuhan, Switzerland Australia Germany Illinois, US China • Core products: • Core products: • Core products: • Core products: • Core products: immunoglobulins & immunoglobulins & human albumin, alb
Slide 13: CapEx investments are providing capacity for growth
CapEx investments are providing capacity for growth CSL expects CapEx investment needs to reduce as major projects are now coming online For personal use only Annual CapEx Spend New Capacity Online 30% CSL Plasma Centers at Start of FY Reduction in IG Production CapEx Spend COVID Dip 330 303 277 237
Slide 14: From donor to patient: Manufacturing plasma biotherapies
From donor to patient: Manufacturing plasma biotherapies For personal use only The process starts Frozen plasma and Plasma and pastes Separation of Reconstitution and with plasma donors plasma pastes are are held in cold whole plasma into filtration to manufacture who play a vital role transported t
Slide 15: Welcome to Broadmeadows
For personal use only WELCOME TO BROADMEADOWS 14
Slide 16: CSL Behring Broadmeadows
CSL BEHRING For personal use only BROADMEADOWS Site opened 1994 Commercial facilities for 1,200+ employees production of PRIVIGEN®, Domestic AlbuRx® and plasma Hizentra® fractionation for Australia, New Recombinant Zealand, Hong manufacturing Kong, Taiwan, facility for clinical Malaysia trial produc
Slide 17: Our Workforce
OUR WORKFORCE For personal use only 1,268 92% 89% EMPLOYEES FULL TIME HOURS PERMANENT EMPLOYEES 40 years 1 in 5 38% AVERAGE AGE EMPLOYEES ARE PEOPLE EMPLOYEES ARE FEMALE MANAGERS 10,368 years 1 in 10 29.5% OF COMBINED SERVICE EMPLOYEES ARE OVER 55 OF PEOPLE MANAGERS YEARS OLD ARE FEMALE 81% 8 years
Slide 18: Our Customers
Our Customers For personal use only GLOBAL COMMERCIAL SUPPLY REGIONAL DOMESTIC SUPPLY Contract Domestic Manufacturing supply agreements: Plasma supplied through CSL Plasma • National Blood Authority (Australia) sourced in the USA • NZ Blood (New Zealand) • Taiwan Blood Services Foundation (Taiwan) F
Slide 19: CSL Behring Broadmeadows facilities
1. Haemophilia and Specialty Products Facility CSL BEHRING (Domestic/Contract) 2. Turner Facility (PRIVIGEN®, Hizentra®) 3. Facility A (AlbuRx®, Alburex®) BROADMEADOWS 4. 5. Facility F (Base Fractionation) Biotech Manufacturing Facility (Recombinant) For personal use only 4 3 2 5 1 18
Slide 20: Product Portfolio
Product Portfolio KEY Current portfolio Future filling capacity CSL Behring Broadmeadows For personal use only Critical Care Immunology Coagulation Albumin solutions Polyvalent immunoglobulins Plasma-derived factor II Human Albumin Behring® Privigen®, Privigen® AU Human Thrombin active substance Alb
Slide 21: More than a decade of sustained growth
MORE THAN A DECADE OF SUSTAINED GROWTH AND ALMOST A$2B IN CAPITAL INVESTMENT For personal use only 2013 2014 2017 2022 FUTURE Filling capacity expansion Ig yield Turner Biotechnology Facility A Facility F Base Albumin Fractionation capacity PRIVIGEN Manufacturing AlbuRx and Logistics expansion Facil
Slide 22: Sustainability Initiatives at Broadmeadows
Sustainability Initiatives at Broadmeadows For personal use only CSL target: 40% reduction of Scope 1&2 emissions by 2030 against a baseline of average emissions across FY19-21 • Power Purchase Agreement for Australian renewable electricity will make a substantial contribution to achieving target •
Slide 23: CSL Behring Broadmeadows Future Vision
CSL BEHRING BROADMEADOWS FUTURE VISION For personal use only 20 million+ vials in 2030 Our Vision A world-class facility and network partner, reliably delivering for Our Patients. Our Mission We deliver live-saving therapies for Our Patients, collaborating globally to continuously improve production
Slide 24: CSL Seqirus: A Global Network
For personal use only CSL Seqirus A Global Network Driven by Our Promise to Protect Public Health Chris Larkins Jonah Smith April 2024 SVP, Global Operations VP Program Lead – Project Banksia
Slide 25: CSL Seqirus growth linked to differentiation strategy
CSL Seqirus growth linked directly to differentiation strategy and core capabilities For personal use only CSL Seqirus historic growth Cornerstones for Success Seasonal Influenza Revenue (US#039;M) 1,500 23% CAGR Real World Differentiation Evidence Strategy Platform 1,000 500 - FY16 FY17 FY18 FY19 FY20
Slide 26: CSL Seqirus four strategic pillars
1. CONTINUED 2. BROADEN OUR GROWTH IN PANDEMIC INFLUENZA BUSINESS For personal use only Opportunities in both new CSL Seqirus’s focus and existing markets to Multi-pathogen pandemic capability within its 4 strategic increase our global footprint pillars drives its near 3. GROW BEYOND 4. INVEST IN SC
Slide 27: In influenza, Seqirus will grow the market through differentiation
In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates For personal use only Historic Trend (US) Expectations COVID-19 • Influenza still has significant unmet need, particularly in paediatric and older adult 2009 populations H1N1 • Immunisation rates will
Slide 28: Continuous innovation to reduce the burden of influenza
CSL Seqirus focused on continuous innovation to reduce the burden of influenza For personal use only Multiple Differentiators Differentiated aH5N1c QIVc Undifferentiated aQIVc aTIV aQIV TIVe sa-mRNA aH5N1 QIVe Development Status: Development Status: • QIVc: 6-month+ age extension • aQIVc: Phase III
Slide 29: Technologies will be complementary
Technologies will be complementary Cell will remain basis of rapid pandemic response for Flu For personal use only SELF-AMPLIFYING CELL-BASED VACCINE MF59 ADJUVANT mRNA VACCINE Squalene 28
Slide 30: sa-mRNA technology differentiates COVID-19 vaccine candidate
sa-mRNA technology differentiates CSL Seqirus COVID-19 vaccine candidate For personal use only Differentiators of sa-mRNA Technology Accelerating to market • Licensing and collaboration agreement Superior response to Omicron strain 1 as a booster in adults vs. approved with Arcturus Therapeutics Inc
Slide 31: CSL Seqirus – Global manufacturing presence
CSL Seqirus – Global manufacturing presence For personal use only Holly Springs Liverpool, Parkville, sa-mRNA CTM, Waltham, NC, US UK Australia NC, US MA, US The world’s largest cell- The U.K.’s only injectable Australia’s first influenza New sa-mRNA clinical trial State-of-the-Art Vaccine based inf
Slide 32: Looking Forward
Looking Forward For personal use only • CSL Seqirus is well positioned to continue its success in influenza: ‒ Capacity development well advanced to support aQIVc launch • Continuous innovation will enable CSL Seqirus to outpace market growth: ‒ aQIVc setting new standard of care ‒ sa-mRNA • sa-mRNA
Slide 33: CSL Seqirus Tullamarine
For personal use only CSL SEQIRUS TULLAMARINE 32
Slide 34: CSL Seqirus Tullamarine
CSL Seqirus Tullamarine New World Class Flu Cell Culture facility in Australia to meet growing demand and pandemic protection For personal use only Project is on target for schedule and budget, with first production in Q1 2026 Cell culture manufacturing Anti-venom production Best-in-class sustainabi
Slide 35: Project Objectives
Project Objectives For personal use only Australian Biosecurity contract: • 10-year Biosecurity contract secured with Australian government, commencing in mid-2026 • Secure onshore manufacturing capability for cell-based pandemic influenza 3 x 5,000 L FCC bioreactors response and secure supply of Pr
Slide 36: Project Scope
Project Scope For personal use only New CSL Seqirus CSL Behring Tullamarine Site Broadmeadows Site • Consolidated Drug Substance & • Pre-filled Syringe and Vial Fill/Finish Formulated Bulk Manufacture • Raw Materials, Chemistry & • Flu Cell Culture (FCC) FUTURE Microbiology Quality Control Testing •
Slide 37: Project Roadmap
Project Roadmap Project Delivery (Engineering) Validation, Licensure & Registration For personal use only • Design • Construction • Process Qualification, Engineering & Media Simulations • Automation • Process Performance Qualification (PPQ) • Commissioning and Qualification • Site Licensure & Produ
Slide 38: Construction Progress
Construction Progress For personal use only Admin & Labs PNS Warehouse FCC Utility Yard 37 Aerial image @ 5 December 2023
Slide 39: Tullamarine Construction Progress
Tullamarine Construction Progress For personal use only • Project achieving milestones • Certificate of Occupancy received for Admin building • Mechanical & electrical installation complete • Full site hand-over to CSL Seqirus on track for April 2024 • FCC and PNS clean rooms practically complete •
Slide 40: Digital Manufacturing
Digital Manufacturing For personal use only Digital Training Advanced Analytics Live Viable Cell Density
Slide 41: Sustainability Certification
Sustainability Certification For personal use only • On site renewable energy CSL Seqirus Tullamarine generation on track for: • Electrification of plant to reduce reliance on fossil fuels ✓ 5 star Green Star rating • Heat recovery from heat - all buildings decontaminated liquid waste ✓ WELL Gold ra
Slide 42: Questions & Answers
For personal use only 41 ANSWERS QUESTIONS &